First Gene Therapy Products Approved in Brazil – Lexology

Brazil has become the first among the Latin American countries to approve the marketing of gene therapy products. Specifically, the Brazilian Health Regulatory Agency (ANVISA) recently granted marketing authorization for Novartis gene therapy products Luxturna and Zolgensma. As published in the Brazilian Federal Register, Luxturna received its marketing authorization on August 6th and a few days later, on August 17th, Zolgensma received its marketing authorization. Prior to ANVISAs final decision, both products had been approved by the Brazilian Technical Commission of Biosafety (CTNBio), which is responsible for evaluating biosafety of Genetically Modified Organisms (GMOs) in Brazil.

Luxturna

Luxturna (voretigene neparvovec) is indicated for the treatment of adult and pediatric (children over 12 months) patients with vision loss caused by bi-allelic retinal pigment epithelium (RPE) mutation-associated hereditary retinal dystrophies. In Brazil, no other therapeutic option available for the treatment of this rare disease until approval of Novartis gene therapy.

It took 232 business days from the submission of the marketing authorization application for ANVISA to provide its decision. As part of the administrative approval procedure, ANVISA and Novartis signed a Term of Commitment to ensure that the company will conduct additional trials with Brazilian patients to continue to monitor the safety and effectiveness of Luxturna on a long-term basis.

Zolgensma

Zolgensma (onasemnogene abeparvovec) is indicated for the treatment of pediatric patients less than 2 years of age with type 1 spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron (SMN1) gene and with bi-allelic mutations in the SMN1 gene and up to 3 copies of the SMN2 gene.

After 149 business days of analysis, ANVISA concluded that the products benefits surpassed its risks and granted the marketing authorization. However, because it is a new gene therapy, the authorization was granted on a exceptional basis, meaning that Novartis is required to send data on Zolgensmas ongoing trials as agreed to in the signed Term of Commitment.

Novartis also commited to conduct additional studies with Brazilian patients to enable the evaluation of whether Zolgensma maintains a positive benefit-risk balance. Additionally, Novartis also agreed to train (i) healthcare professionals who will perform infusions of the drug; and (ii) Brazilian hospitals in the appropriate storage and handling of Zolgensma.

Regulatory framework and next steps

The Brazilian regulatory framework on advanced therapeutic products is very new. At the end of 2018, ANVISAs Collegiate Board of Directors approved Rule #260/2018, which defines the technical standards for conducting clinical trials with experimental advanced therapy products. On February 26, 2020, ANVISAs Rule #338/2020 was published which provides the requirements for obtaining a marketing authorization for advanced therapy products. The regulation classifies advanced therapy products into three different categories: (i) advanced cell therapy; (ii) gene therapy; and (iii) tissue engineering. Both Luxturna and Zolgensma fall into the second category, gene therapy.

The next step for Novartis to introduce Luxturna and Zolgensma into the Brazilian market involves receiving price approval from the Brazilian Drugs Market Regulation Chamber (CMED). This approval is expected by the end of 2020. There is much anticipation regarding the pricing of these drugs, particularly since Zolgensma is currently considered to be the worlds most expensive drug (at USD $2.125 million).

The approval of the first gene therapy products in Brazil also brings up the issue of whether these drugs will become available in the Public Healthcare System (SUS). The analysis of whether a drug is incorporated into the SUS is conducted by the National Commission for Incorporation of Health Technologies (CONITEC), which issues a recommendation to the Ministry of Health. While Luxturna and Zolgensma are currently not in the SUS, the Brazilian population can obtain free access to these products through a court order.

Although there are still some a few steps to be taken until Luxturna and Zolgensma truly get into the hands of patients in Brazil, the approval itself and the consolidation of a regulatory framework on advanced therapeutic products is expected to promote the development of this pharmaceutical in Brazil.

Read more:

First Gene Therapy Products Approved in Brazil - Lexology

Gene Therapy Market is projected to be worth USD 10 Billion by 2030, growing at an annualized rate of over 40% – The News Brok

The success of the approved gene therapies has led to an upward surge in the interest of biopharmaceutical developers in this field, resulting in a significant boost in clinical research initiatives and several high value acquisitions

Roots Analysis has announced the addition of Gene Therapy Market (3rd Edition), 2019-2030 report to its list of offerings.

Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA (AveXis) and ZYNTEGLO (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.

To order this 550+ page report, which features 190+ figures and 355+ tables, please visit this link

Around 470 gene therapies are currently under developmentNearly 45% of pipeline drugs are in the clinical phase, while rest are in the preclinical / discovery stage. Gene augmented therapies presently represent 66% of the total number of such interventions that are in the pipeline. It is worth mentioning that majority of such product candidates are being developed as in vivo gene therapies.

More than 30% of clinical stage pipeline therapies are being designed for treating oncological disordersConsidering the overall pipeline, over 20% of product candidates are being developed to treat various types of cancers, followed by those intended for the treatment of metabolic (15%) and ophthalmic disorders (12%). It is also worth highlighting that adenovirus vectors are presently the preferred vehicles used for the delivery of anticancer gene therapies.

Over 60% of gene therapy developers are based in North AmericaOf the 110 companies developing gene therapies in the abovementioned region, 64 are start-ups, 26 are mid-sized players, while 18 are large and very large companies. Further, within this region, most of the developers are based in the US, which has emerged as a key R&D hub for advanced therapeutic products.

More than 31,000 patents have been filed / published related to gene therapies, since 2016Of these, 17% of patent applications / patents were related to gene editing therapies, while the remaining were associated with gene therapies. Leading assignees, in terms of the size of intellectual property portfolio, include (industry players) Genentech, GSK, Sangamo Therapeutics, Bayer and Novartis, (non-industry players) University of California, Massachusetts Institute of Technology, Harvard College, Stanford University and University of Pennsylvania.

USD 16.5 billion has been invested by both private and public investors, since 2014Around USD 3.3 billion was raised through venture capital financing, representing 20% of the total capital raised by industry players till June 2019. Further, there have been 28 IPOs, accounting for more than USD 2.2 billion in financing of gene therapy related initiatives. These companies have also raised significant capital in secondary offerings.

30+ mergers / acquisitions have been established between 2014 and 2019Examples of high value acquisitions reported in recent past include the acquisition of AveXis by Novartis (2018, USD 8,700 million) and Bioverativ by Sanofi (2018, USD 11,600 million).

North America and Europe are anticipated to capture over 85% of market share by 2030With a promising development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 40% during the next decade. In addition to North America and Europe, the market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

The USD 10 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom gene therapies are likely to be the most promising treatment options for genetic disorders. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles, featuring an overview of the therapy, current development status and clinical results. Each profile includes information on therapeutic indication, targeted gene, route of administration, special designations, mechanism of action, dosage, patent portfolio, technology portfolio, clinical trials and recent developments (if available).

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

or email [emailprotected]

You may also be interested in the following titles:

Contact:Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 1091[emailprotected]

Link:

Gene Therapy Market is projected to be worth USD 10 Billion by 2030, growing at an annualized rate of over 40% - The News Brok

Prevail Therapeutics to Present at Upcoming Investor Conferences – Yahoo Finance

Citi 15th Annual BioPharma Conference, Morgan Stanley 18th Annual Global Healthcare Conference and Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the Company will participate in the following upcoming virtual investor conferences in September:

Webcasts of the presentations will be available under "Events and Presentations" in the Investors and Media section of the Company's website at ir.prevailtherapeutics.com following the presentations.

About Prevail TherapeuticsPrevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The Company is developing PR001 for patients with Parkinsons disease with GBA1mutations (PD-GBA) and neuronopathic Gaucher disease; PR006 for patients with frontotemporal dementia withGRNmutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.

Prevail was founded by Dr.Asa Abeliovichin 2017, through a collaborative effort withThe Silverstein Foundationfor Parkinsons with GBA and OrbiMed, and is headquartered inNewYork, NY.

Forward-Looking Statements Related to PrevailStatements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning the potential for Prevails gene therapy candidates to transform the treatment of patients with, and slow or halt the progression of, FTD-GRN and other neurodegenerative diseases. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Prevails novel approach to gene therapy makes it difficult to predict the time, cost and potential success of product candidate development or regulatory approval; Prevails gene therapy programs may not meet safety and efficacy levels needed to support ongoing clinical development or regulatory approval; the regulatory landscape for gene therapy is rigorous, complex, uncertain and subject to change; the fact that gene therapies are novel, complex and difficult to manufacture; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in Prevails filings with the Securities and Exchange Commission (SEC), including the Risk Factors section of the Companys Quarterly Report on Form 10-Q for the period ended June 30, 2020, filed with the SEC on August 11, 2020, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Prevail undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:Mary CarmichaelTen Bridge Communications mary@tenbridgecommunications.com 617-413-3543

Investor Contact:investors@prevailtherapeutics.com

See the rest here:

Prevail Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance

Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I – BioSpace

Data on all eight patients demonstrate sustained engraftment and supranormal IDUA enzyme expression

Translation of metabolic correction to clinical outcomes in first two patients continues to support potential of hematopoietic stem cell gene therapy in a second neurometabolic disorder

Data support planned initiation of registrational trial in 2021

BOSTON and LONDON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics(Nasdaq: ORTX), a global gene therapy leader, today announced additional interim data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, an investigationalex vivoautologous hematopoietic stem cell (HSC) gene therapy in development for the treatment of mucopolysaccharidosis type I (MPS-I) at theSan Raffaele Telethon Institute for Gene Therapy(SR-Tiget) inMilan, Italy. The readout from the primary endpoint at one year of follow-up is expected in 2021. Today's results are being shared virtually in an invited oral presentation at the 46th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT).

We continue to see encouraging data from the ongoing clinical trial in MPS-I, including promising preliminary clinical effects on motor development, acquisition of cognitive skilIs and growth in the first two patients that were treated now 1.5 and 2 years ago, respectively. Additionally, new preliminary analyses of radiological outcome measures suggest that treatment with OTL-203 leads to stabilization or improvement in disease-related neurological abnormalities, as measured by brain and spine MRI, which we look to confirm with longer follow-up, saidMaria Ester Bernardo, M.D., Ph.D., principal investigator at SR-Tiget. "These data, taken together with those from clinical studies of HSC gene therapy for other metabolic disorders and leukodystrophies, support the potential for this therapeutic approach to correct a wide spectrum of multisystemic manifestations of the disease, bringing clinically meaningful benefits for patients.

Interim Study Results

Eight patients with the severe Hurler subtype of MPS-I had been treated with OTL-203 in the ongoing proof-of-concept study, which completed enrollment in December 2019. As of July 2020, all patients had been followed for a minimum of six months, with the longest follow-up extending out to 24 months. Treatment with OTL-203 was generally well-tolerated with a safety profile consistent with the selected conditioning regimen. Consistent with previous analyses, treatment across all eight patients continued to demonstrate:

We continue to see positive trends in all biomarker and clinical measures as we follow patients in the OTL-203 proof of concept study for longer periods of time, saidBobby Gaspar, M.D., Ph.D., chief executive officer of Orchard. With a growing amount of data to support advancing this program, we have recently convened a panel of disease experts to develop a design for a registrational trial that we intend to take to the regulators in advance of initiating the study in 2021 and ultimately progressing towards commercialization.

About OTL-203 and MPS-I

Mucopolysaccharidosis type I (MPS-I) is a rare, inherited neurometabolic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) lysosomal enzyme, which is required to break down sugar molecules called glycosaminoglycans (also known as GAGs). The accumulation of GAGs across multiple organ systems results in symptoms including neurocognitive impairment, skeletal deformity, loss of vision and hearing, and cardiovascular and pulmonary complications. MPS-I occurs at an overall estimated frequency of one in every 100,000 live births. There are three subtypes of MPS-I; approximately 60 percent of children born with MPS-I have the most severe subtype, called Hurler syndrome, and rarely live past the age of 10 when untreated.

Treatment options for MPS-I include hematopoietic stem cell transplant and chronic enzyme replacement therapy, both of which have significant limitations. Though early intervention with enzyme replacement therapy has been shown to delay or prevent some clinical features of the condition, it has only limited efficacy on neurological symptoms. OTL-203 is an investigationalex vivoautologous hematopoietic stem cell gene therapy being studied for the treatment of MPS-I. Orchard was granted an exclusive worldwide license to intellectual property rights to research, develop, manufacture and commercialize the gene therapy program for the treatment of MPS-I developed by theSan Raffaele Telethon Institute for Gene TherapyinMilan, Italy.

About Orchard

Orchard Therapeuticsis a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Ourex vivoautologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and theSan Raffaele Telethon Institute for Gene Therapy inMilan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters inLondonandU.S.headquarters inBoston. For more information, please visitwww.orchard-tx.com, and follow us onTwitterandLinkedIn.

Availability of Other Information About Orchard

Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (TwitterandLinkedIn), including but not limited to investor presentations and investor fact sheets,U.S. Securities and Exchange Commissionfilings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking Statements

This press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as anticipates, believes, expects, plans, intends, projects, and future or similar expressions that are intended to identify forward-looking statements. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, the therapeutic potential of Orchards product candidates, including the product candidates referred to in this release, Orchards expectations regarding the timing of clinical trials for its product candidates, including the product candidates referred to in this release, the timing of interactions with regulators and regulatory submissions related to ongoing and new clinical trials for its product candidates, the timing of announcement of clinical data for its product candidates, and the likelihood that such data will be positive and support further clinical development and regulatory approval of these product candidates. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development, its supply chain and commercial programs; the risk that Orchard will not realize the anticipated benefits of its new strategic plan or the expected cash savings associated with such plan; the risk that any one or more of Orchards product candidates, including the product candidates referred to in this release, will not be successfully developed, approved or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates or that long-term adverse safety findings may be discovered; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; and the risk of delays in Orchards ability to commercialize its product candidates, if approved. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter endedJune 30, 2020, as filed with theU.S. Securities and Exchange Commission(SEC), as well as subsequent filings and reports filed with theSEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com

MediaMolly CameronManager, Corporate Communications+1 978-339-3378media@orchard-tx.com

The rest is here:

Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I - BioSpace

AGTC to Host Management Update on September 9 at 8:00 am ET to Discuss Planned Phase 2/3 XLRP Trial, Share Additional XLRP Data and Report Fourth…

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will provide a management update on its planned Phase 2/3 X-Linked Retinitis Pigmentosa (XLRP) clinical trial design, a re-analysis of dose Groups 2 and 4 data, and new preliminary visual sensitivity data from Group 5; data from Group 5 is in advance of the full interim data analysis that the Company expects to provide in 4Q 2020 for both Groups 5 and 6. The Company will also report financial results for the fiscal quarter and year ended June 30, 2020 before the market opens on Wednesday, September 9, 2020. AGTC management will host a conference call and webcast with accompanying slides beginning at 8:00am Eastern Time on the same date.

To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). A live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Companys most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its pre-clinical programs build on the Companys industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in larger ophthalmology indications, optogenetics, otology and CNS disorders.

About X-linked Retinitis Pigmentosa (XLRP)

XLRP is an inherited condition that causes progressive vision loss in boys and young men. Characteristics of the disease include night blindness in early childhood and progressive constriction of the visual field. In general, XLRP patients experience a gradual decline in visual acuity over the disease course, which results in legal blindness around the 4th decade of life. AGTC was granted U.S. Food and Drug Administration (FDA) orphan drug designation in 2017, as well as European Commission orphan medicinal product designation in 2016, for its gene therapy product candidate to treat XLRP caused by mutations in the RPGR gene.

Forward-Looking Statements

This release contains forward-looking statements that reflect AGTC's plans, estimates, assumptions and beliefs, including statements regarding the timing for and expected expansion of its XLRP clinical development program, the timing for reporting data in its XLRP and ACHM clinical programs, and its ability to enroll patients, effectively design and successfully complete its ongoing clinical trials. Forward-looking statements include information concerning possible or assumed preclinical and clinical product development and regulatory progress, future results of operations, financial guidance, business strategies and operations, potential growth opportunities, potential market opportunities, the effects of competition and the impact of the COVID-19 pandemic. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors. Risks and uncertainties that may cause actual results to differ materially include, among others: gene therapy is still novel with only a few approved treatments so far; AGTC cannot predict when or if it will obtain regulatory approval to commercialize a product candidate or receive reasonable reimbursement; uncertainty inherent in clinical trials and the regulatory review process; risks and uncertainties associated with drug development and commercialization; the direct and indirect impacts of the ongoing COVID-19 pandemic on the Companys business, results of operations, and financial condition; factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading "Risk Factors" in the Companys most recent annual or quarterly report and in other reports AGTC has filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, AGTC assumes no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

IR/PR CONTACTS:David Carey (IR) or Glenn Silver (PR)Lazar FINN PartnersT: (212) 867-1768 or (646) 871-8485david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contact:Bill SullivanChief Financial OfficerApplied Genetic Technologies CorporationT: (617) 843-5728bsullivan@agtc.com

Stephen PotterChief Business OfficerApplied Genetic Technologies CorporationT: (617) 413-2754spotter@agtc.com

Original post:

AGTC to Host Management Update on September 9 at 8:00 am ET to Discuss Planned Phase 2/3 XLRP Trial, Share Additional XLRP Data and Report Fourth...

The Safety and Clinical Activity of Gene-engineered T-cell Therapy Targeting HPV-16 E7 in Epithelial Cancers – Pharmacy Times

The Safety and Clinical Activity of Gene-engineered T-cell Therapy Targeting HPV-16 E7 in Epithelial Cancers

Investigators presented the study results during the 2020 American Society of Clinical Oncology Virtual Scientific Program.1

In prior research, genetically engineered T-cell therapy demonstrated significant clinical activity in hematologic malignancies. However, the investigators of this study noted that it is currently not known whether this treatment has efficacy when applied to epithelial cancers. This would be an important treatment application as epithelial cancers account for 80% to 90% of human malignancies, according to the presenters.

In order to investigate this treatment application further, the investigators conducted a phase 1 clinical trial with a 3+3 dose escalation.

In this trial, patients with metastatic HPV-16+ epithelial cancers received a single infusion of genetically engineered T cells expressing a T-cell receptor targeting an HLA-A*02:01-restricted epitope of HPV-16 E7 (E7 TCR-T cells). Before cell infusion, a lymphocyte-depleting conditioning regimen was administered, and following cell infusion, high-dose systemic aldesleukin was administered.

The study participants consisted of 12 patients who had received prior treatment with a median of 4 (range of 3 to 7) anticancer agents. The cell dose was not limited by toxicity.

Objective clinical responses were seen in 6 patients, with observed responses including regression of bulky tumors and complete elimination of some tumors. These responses were seen in patients with vulvar, anal, head and neck, and cervical cancer.Of those patients who previously received PD-1-based therapy, 4 responded, with the duration ranging from 3 to 9 months. The observed responses in these patients was a sustained, high-level engraftment of E7 TCR-T cells in peripheral blood. After approximately 6 weeks, the median response was observed to be approximately 66% of total T cells, ranging from 1% to 88%. This response was found to correlate with cell dose but not with clinical response, although infused T-cell characteristics did not correlate significantly with clinical response.

Three of 4 resistant tumors studied demonstrated genetic defects in HLA-A*02:01 or B2M, which are necessary components of the target complex. Of these 3, 1 demonstrated copy loss with decreased expression of antigen presentation and interferon response molecules, including TAP1, TAP2, IFNGR1, and IFNGR2 molecules. However, none of the 3 sensitive tumors studied showed genetic defects in any of these molecules.REFERENCENorberg S, Nagarsheth N, Sinkoe A, et al. Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers. J Clin Oncol. 2020;38(suppl 15):101. doi: 10.1200/JCO.2020.38.15_suppl.101

The rest is here:

The Safety and Clinical Activity of Gene-engineered T-cell Therapy Targeting HPV-16 E7 in Epithelial Cancers - Pharmacy Times

Qualitative Analysis and Competitive Industry, CCOVID-19 Scenario of Personalized Gene Therapy Treatment Market – The News Brok

Prophecy Market Insights Personalized Gene Therapy Treatment market research report provides a comprehensive, 360-degree analysis of the targeted market which helps stakeholders to identify the opportunities as well as challenges. The research report study offers keen competitive landscape analysis including key development trends, accurate quantitative and in-depth commentary insights, market dynamics, and key regional development status forecast 2020-2029. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses.

Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/61

An executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Personalized Gene Therapy Treatment market

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Segmentation Overview:

Personalized Gene Therapy TreatmentMarket Key Companies:

Amgen, Inc., Chengdu Shi Endor Biological Engineering Technology Co., Ltd., SynerGene Therapeutics, Inc., Cold Genesys, Inc., Bellicum Pharmaceuticals, Inc., Takara Bio, Inc.,Ziopharm Oncology, Inc., , Sevion Therapeutics, Inc., OncoSec Medical, Inc., and Burzynski Clinic.

The Personalized Gene Therapy Treatment research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Personalized Gene Therapy Treatment market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/61

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. This report is a must-read for investors, entrepreneurs, consultants, researchers, business strategists, and all those who have any kind of stake or are planning to foray into the Personalized Gene Therapy Treatment industry in any manner.

Key Questions Answered in Report:

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

See more here:

Qualitative Analysis and Competitive Industry, CCOVID-19 Scenario of Personalized Gene Therapy Treatment Market - The News Brok

Sorrento Announces the Closing of Its Acquisition of SmartPharm to Build Next Generation G-MAB-Encoded Plasmid DNA For Cost-Efficient and In Vivo…

SAN DIEGO and BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) and SmartPharm Therapeutics, Inc. (SmartPharm) announced today that Sorrento has completed the acquisition of SmartPharm, a gene-encoded protein therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases with broad potential application in enhancing any antibody-centric therapeutics.

The platform in synergy with Sorrentos industry-leading fully human G-MAB antibody library has the potential to be the engine for the next-generation, cost-effective in vivo production of antibody therapeutics in patients. By encoding the antibody sequence into a plasmid, a single injection into someones muscle could potentially lead the person to make their own antibodies in vivo for months, instead of relying on repeat administrations of an externally manufactured antibody.

We are very encouraged by the preclinical data generated thus far by our STI-2020dna plasmid candidate against COVID-19, said Henry Ji, Ph.D., CEO of Sorrento Therapeutics. But beyond STI-2020dna the integration of the plasmid DNA technology with our existing antibody products has the potential to make antibody therapy much more accessible and affordable for patients, and is applicable to a multitude of indications ranging from cancer to infectious diseases.

The current SmartPharm R&D and senior management team will remain in place and is expected to integrate into the Sorrento research, development, and corporate infrastructure.

The merger was completed on September 1, 2020 and at such time, SmartPharm became a wholly owned subsidiary of Sorrento. The total value of the consideration payable to the holders of capital stock of SmartPharm in the merger was $19.4 million, subject to certain adjustments for net working capital, indebtedness, transaction expenses and cash. Upon completion of the merger, SmartPharm stockholders became entitled to receive an aggregate of approximately 1.76 million shares of Sorrento common stock based on a price per share equal to $10.60.

About SmartPharm Therapeutics

SmartPharm Therapeutics, Inc. is a privately held, development stage biopharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of serious or rare diseases with the vision of creating Biologics from Within. SmartPharm is currently developing a novel pipeline of non-viral, gene-encoded proteins for the treatment of conditions that require biologic therapy such as enzyme replacement and tissue restoration. SmartPharm commenced operations in 2018 and is headquartered in Cambridge, MA, USA. For more information, please visit http://www.smartpharmtx.com.

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB library"), clinical stage immuno-cellular therapies ("CAR-T", "DAR-T"), antibody-drug conjugates ("ADCs"), and clinical stage oncolytic virus ("Seprehvir"). Sorrento is also developing potential coronavirus antiviral therapies and vaccines, including COVIDTRAP, ACE-MAB, COVI-MAB, COVI-GUARD, COVI-SHIELD and T-VIVA-19; and diagnostic test solutions, including COVI-TRACK and COVI-TRACE. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and ZTlido (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido was approved by the FDA on February 28, 2018.

For more information, visit http://www.sorrentotherapeutics.com

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related toSorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the potential effects that the acquisition of SmartPharm may have on Sorrentos business and product candidate pipeline; the data read-outs related to ongoing studies for COVID-19 using antibodies and gene-encoded antibodies; the potency and potential therapeutic capabilities of gene-encoded antibodies and STI-2020dna, and their respective impact on SARS-CoV-2; the expected length of any therapeutic benefit or antiviral protection provided by gene-encoded antibodies and STI-2020dna; the potential administration and applications for a range of disease indications of gene-encoded antibodies and STI-2020dna, alone or in combination; the status of preclinical testing for STI-1499 and STI-2020dna; the therapeutic potential of gene-encoded antibodies, and STI-2020dna for SARS-CoV-2 and COVID-19; the potential costs and cost-effectiveness associated with STI-2020dna and other DNA plasmids; Sorrentos ability to produce antibody candidates against pathogens and cancer cells; Sorrentos ability to transition from product development to full scale manufacturing and commercialization; Sorrentos ability to advance SmartPharms non-viral gene therapy technology and its gene-encoded platform technology; Sorrentos ability to combine SmartPharms technology with Sorrentos technology and manufacturing capabilities; and Sorrentos potential position in the biopharmaceutical industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's technologies and prospects with newly acquired technologies, including the acquisition of SmartPharm and the utilization of SmartPharms Gene-Encoded Therapeutics (GET) platforms for the treatment and prevention of coronavirus infections and other pathogens and cancer cells; risks related to seeking regulatory approvals and conducting clinical trials; the clinical and commercial success of the treatment and prevention of coronavirus infections using gene-encoded antibodies; the viability and success of using gene-encoded antibodies for treatments in anti-viral therapeutic areas, including coronavirus; clinical development risks, including risks in the progress, timing, cost and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that prior study and trial results may not be replicated in future studies and trials; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks related to seeking regulatory approvals and conducting clinical trials; risks of manufacturing drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its strategies; risks related to the global impact of COVID-19 and other risks that are described in Sorrento's most recent periodic reports filed with theSecurities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year endedDecember 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with theSecurities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations

Alexis Nahama, DVM (SVP Corporate Development)Telephone: 1.858.203.4120Email: mediarelations@sorrentotherapeutics.com

Sorrento and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.G-MAB, COVI-GUARD, COVI-SHIELD, COVIDTRAP, T-VIVA-19, COVI-MAB, ACE-MAB, COVI-TRACK, and COVI-TRACE are trademarks of Sorrento Therapeutics, Inc.

ZTlido is a trademark owned by Scilex Pharmaceuticals Inc.All other trademarks are the property of their respective owners. 2020 Sorrento Therapeutics, Inc. All Rights Reserved.

Originally posted here:

Sorrento Announces the Closing of Its Acquisition of SmartPharm to Build Next Generation G-MAB-Encoded Plasmid DNA For Cost-Efficient and In Vivo...

Walnuts expect to hit 780000 tons – Foothills Sun Gazette

The forecast is based on 380,000 bearing acres, up 4% from 2019s estimated bearing acreage of 365,000.

A warm and dry January and February meant growers started irrigating early. The 2020 chilling hours were low. Leaf-out was prolonged, which resulted in uneven canopy and nut development. April rains increased blight risk. Nut sets looked good, with reports of tree limbs heavy with nuts. Harvest is expected to begin in early September, ahead of last year.

Survey data indicated an average nut set per tree of 1,197, up 22% from 2019s average of 983. However, growers fear a larger crop will continue to bring prices down.

Lumber prices have surged to a fresh record high of $932 per 1000 board feet in August amid continuing high demand from the renovation and new home markets. Prices are triple what they were in May. Alongside the strong demand were a supply shortage as mills failed to anticipate the coronavirus pandemic setting off a building boom.

Sunshine Reality/Dimension Energy plans to erect a 4-megawatt solar farm at 7227 West Doe on 20 acres in the Visalia Industrial Park. The project is part of Southern California Edisons community solar program.

Californias Employment Development Department reports that agricultural employment in 2020 was 20% to 30% lower than in 2019, with the largest drop in June 2020.

The reductions in agricultural employment varied by county. Agricultural employment in Fresno County was down five percent in spring and summer 2020 compared the same period of 2019, down 25 to 35 percent in Kern County, and down 35 to 45 percent in Monterey County.

In Tulare County as of July there were 12,100 fewer farm jobs compared to July 2019, the height of the summer harvest season for many crops. There were 27,100 workers in the fields vs 39,2000 the year before. That is about a one third decline.

Kings County was hit less hard with farm jobs dropping 1,000 from 8,200 to 7,200 in July, year over year.

Observers say grocery store sales for many crops are higher but restaurant sales are way down.

Starbucks has opened a location in Goshen east of the new Betty Drive interchange. It the latest national retailer to see a future in this Hwy 99 community. In the works are two large fueling stations with more food choice including a new Burger King.

Rogers Jewelers may be gone from Caldwell Avenue in Visalia but a next door furniture store will expand into the 5,000-square foot space says property owner George Ouzounian. Mattress specialists Drop Box has leased the space and will expand their retail store in Visalia.

Homeless advocates Salt and Light, based in Tulare, are negotiating with Tulare County to site a micro-home village in Visalia. The potential site includes locations both north and south of the county owned Government Plaza complex on south Mooney on open land. The nonprofit plans to build intentional, master-planned communities designed to lift people experiencing chronic homelessness off the streets of Tulare County.

The rest is here:

Walnuts expect to hit 780000 tons - Foothills Sun Gazette

Washington University bolsters its promise to St. Louis community – Washington University in St. Louis Newsroom

Webber

Washington University in St. Louis is taking a significant step toward fulfilling its promise to be in St. Louis and for St. Louis by reorienting its top administrative structure to create an executive leadership position for the universitys regional efforts.

Henry S. Webber, executive vice chancellor and chief administrative officer, will transition to the newly created role of executive vice chancellor for civic affairs and strategic planning, with a sharp focus on regional equitable economic development, community engagement and partnership with the universitys neighborhoods and civic and community leaders.

As an institution, we have made a commitment to the St. Louis region to double down on our role and impact in the community. It is now time to make good on that promise, and we are ready to move forward in a big way to strengthen our community partnerships and our desire to be Washington University not just in St. Louis, but for and with St. Louis, Chancellor Andrew D. Martin said. Hank Webber is an innovative leader, an accomplished scholar, and the absolute best person to lead us into this new phase. I am extraordinarily grateful to Hank for lending his talents to this incredibly important effort, and I know our communities both Washington University and the greater St. Louis region will be all the better as a result of his leadership.

St. Louis is our home and it is critically important to us both as an institution and as individual community members that it should succeed and thrive, Webber said. That means focusing on both the regions many strengths and also our deep challenges, including racial segregation and large income and health disparities. We know we can only achieve our goals through a true partnership, which means listening to one another and learning from our shared history as we build on the strong foundation. If we are to succeed in our goal to be for and with St. Louis, it must be a two-way street. We are committed to doing our part, and I am convinced that together we can make a great difference in economic opportunity in St. Louis in the years ahead.

In his new role, Webber will be responsible for developing and implementing the WashU Compact, a commitment between the university and the greater St. Louis region as the university looks to strengthen its community partnerships. He will have primary responsibility for university initiatives and units that are most directly focused on the St. Louis community and university planning, including the Office of the University Architect and Planner; the Academy for Diversity, Equity, and Inclusion; Edison Theatre; the Institute for School Partnership; the university ombudsman; real estate operations and development; capital projects; sustainability; and the Washington University Police Department.

He will share responsibility for the Office of Community and Government Affairs with the chancellor, and hell share responsibility for the Gephardt Institute for Civic and Community Engagement and University College with the provost. Among his first priorities will be to initiate a universitywide planning process, to be informed by and closely coordinated with the universitys strategic plan, which will include a significant focus on engagement with the St. Louis community.

Since coming to Washington University in 2008, Webber has led the development of the universitys real estate master plan; administrative cost-efficiency strategy; long-term housing strategy; and sustainability master plans; and he leads, along with the provost and chief financial officer, the university budget process. He has played a leading role and serves as board chair of Cortex, a 200-acre urban technology redevelopment district that is home to 425 companies and 6,200 jobs, and the growth of the KIPP charter school network in St. Louis.

I have been encouraged and inspired by Washington Universitys aspiration to be not only in St. Louis, but for St. Louis. It has been clear from the start that there is great sincerity and conviction in that goal, said Sam Fiorello, president and chief executive officer of Cortex. The university is a tremendous asset in our region, and if we are to achieve our collective goal of making St. Louis a better place for all of our citizens, it is extremely important for us to work together to derive solutions and create opportunities.

On a personal note, I know Hank Webber to be a smart and passionate leader who understands the nuances of what we are trying to accomplish, such as strengthening and growing our workforce, training entrepreneurs and, importantly, being more intentional in our desire to become a more diverse and inclusive region. I am so pleased that he will be focusing more of his energy and talent to bring to bear Washington Universitys considerable resources and excellence for the betterment of our region.

Webber, who also is a professor of practice at the Brown School and the Sam Fox School of Design & Visual Arts, is a nationally recognized expert in community engagement and development. As a faculty member, he teaches courses on topics including urban development, health policy, strategic management and social welfare policy. His scholarly research has centered around community development, mixed-income housing, racial and income segregation and the role of anchor institutions in urban communities.

Prior to his appointment at Washington University in 2008, Webber spent 21 years at the University of Chicago, including as vice president for community and government affairs. Under his guidance, the University of Chicagos community affairs program was recognized in a national study as one of the dozen strongest programs in the United States.

Webber will continue to serve on several nonprofit boards in the St. Louis region, including as chair of the board of directors of Cortex. He also serves as chair of the board of the Washington University Medical Center Redevelopment Corp. and Invest STL, the St. Louis regional community-development initiative. He is on the boards of directors of Forest Park Forever, Downtown Partnership, Provident, RISE and the Jewish Federation of St. Louis. He previously served on the board of directors of Shorebank, the largest community development bank in the United States.

A graduate of Brown University, Webber earned a masters degree in public policy from Harvard Universitys John F. Kennedy School of Government.

A search committee will be formed to identify candidates to succeed Webber in his current role. In the meantime, he will continue to lead most of the key areas in his portfolio.

Go here to see the original:

Washington University bolsters its promise to St. Louis community - Washington University in St. Louis Newsroom

SIUE Receives 2020 Higher Education Excellence In Diversity Award – RiverBender.com

EDWARDSVILLE Southern Illinois University Edwardsville has received the 2020 Higher Education Excellence in Diversity (HEED) Award from INSIGHT Into Diversity magazine, the oldest and largest diversity-focused publication in higher education. SIUE joins a select group of 33 institutions that have earned the distinction for seven consecutive years.As a recipient of the annual HEED Award, a national honor recognizing U.S. colleges and universities that demonstrate an outstanding commitment to diversity and inclusion, SIUE will be featured along with 90 other recipients in the November 2020 edition of INSIGHT Into Diversity magazine.

The HEED Award process consists of a comprehensive and rigorous application that includes questions relating to the recruitment and retention of students and employees and best practices for both continued leadership support for diversity, and other aspects of campus diversity and inclusion, said Lenore Pearlstein, publisher of INSIGHT Into Diversity magazine. We take a detailed approach to reviewing each application in deciding who will be named a HEED Award recipient. Our standards are high, and we look for institutions where diversity and inclusion are woven into the work being accomplished every day across their campuses.

INSIGHT Into Diversity magazine selected SIUE based on its exemplary diversity and inclusion initiatives, and the ability to embrace a broad definition of diversity on campus, including gender, race, ethnicity, veterans, people with disabilities, members of the LGBTQIA+ community and others.

SIUEs strong commitment to diverse programming, equitable practices, and our diversity and inclusion online learning community position the University as a model for the region, said Venessa A. Brown, PhD, associate chancellor and chief diversity officer. SIUE values and appreciates a diverse and inclusive campus community. We are intentional about discussing various issues in our state, region, nation and world that impact our campus culture.

Brown said SIUEs annual Diversity Day on Thursday, Oct. 15 will be delivered in a virtual environment for the first time.

SIUEs diversity programming during the 2019-20 academic year included: DiversityEdu Learning Courses for campus community members, Hispanic Heritage Month, the newly formed Anti-Racism Task Force, the continuing Implicit Bias Series, National Coming Out Day, the Inaugural Ed Roberts Champions of Accessibility Celebration Dinner, National Disability Employment Awareness Month and World AIDS Day.

For more information about the magazine, visit insightintodiversity.com

About INSIGHT Into Diversity

INSIGHT Into Diversity magazine is the oldest and largest diversity publication in higher education today and is well-known for its annual Higher Education Excellence in Diversity (HEED) Award, the only award recognizing colleges and universities for outstanding diversity and inclusion efforts across their campuses. In addition to its online job board, INSIGHT Into Diversity presents timely, thought-provoking news and feature stories on matters of diversity and inclusion across higher education and beyond. Articles include interviews with innovators and experts, as well as profiles of best practices and exemplary programs. Readers will also discover career opportunities that connect job seekers with institutions and businesses that embrace a diverse and inclusive workforce. Current, archived, and digital issues of INSIGHT Into Diversity magazine are available online at insightintodiversity.com.

Southern Illinois University Edwardsville provides students with a high quality, affordable education that prepares them for successful careers and lives of purpose to shape a changing world. Built on the foundation of a broad-based liberal education, and enhanced by hands-on research and real-world experiences, the academic preparation SIUE students receive equips them to thrive in the global marketplace and make our communities better places to live. Situated on 2,660 acres of beautiful woodland atop the bluffs overlooking the natural beauty of the Mississippi Rivers rich bottomland and only a short drive from downtown St. Louis, the SIUE campus is home to a diverse student body of more than 13,000.

Photo: Venessa A. Brown, PhD, SIUE associate chancellor and chief diversity officer.

Like RiverBender.com on Facebook!

Print Version Submit a News Tip

Link:

SIUE Receives 2020 Higher Education Excellence In Diversity Award - RiverBender.com

Why Im leaving The Forward to become a rabbi – Forward

My grandparents were concerned for my safety amidst a steady rise in attacks. My parents worried about long hours with little gratitude. My brother warned of trends indicating I was entering an unstable and shrinking job market.

I decided to become a journalist anyway.

Working at The Forward was the fulfillment of a childhood dream, ever since I did a fourth-grade book report on a collection of letters to A Bintel Brief. That book sat in a place of honor on my desk back when I still had a desk, when we still had an office, when we didnt fully understand how much our actions affect each other, and how much we need community.

Now, after three and a half years at The Forward and seven in the business, Im leaving journalism to go to rabbinical school. I start next week as one of 17 members of the Jewish Theological Seminary class of 2025.

I began exploring the idea of becoming a rabbi after two profound spiritual experiences I had on assignment: at morning minyan in Pittsburgh the day after the synagogue shooting that killed 11 in 2018, and during Kabbalat Shabbat at an Air Force base in Texas three months later. On both occasions, though I was there as an outside observer, I was struck by the power of intentional community, the invisible alchemy of holy togetherness that unites friends and strangers who feel an ancient, indescribable longing to connect to God and, even more importantly, to each other. As we know from the rules of a minyan, the quorum that Jewish law requires for certain prayers and as weve especially realized this year doing Jewish is incomplete if not done together.

Im embarking on this journey for the same reason I came to The Forward in the first place: I love Jews, I love learning, and I want to use what I learn to serve the community I love.

Being a Jewish journalist allowed me to learn from Jews every day. From college students and seasoned political insiders, from grassroots activists and nonprofit executives, from mavens and machers and moochers and meshuggeners, I learned how the world works for Jews and how the Jewish world works and often, how it doesnt. Id like to think Rabbi Ben Zoma was thinking of journalists when he asked, Who is wise? One who learns from everyone. (He was definitely thinking of journalists on Twitter when he asked, Who is strong? One who controls his impulses.)

I hope to take what I have learned, and what I will learn, and help build and grow the types of intentional Jewish communities like those I encountered in Pittsburgh and Texas, like those Ive reported about at universities, summer camps, protests and synagogues of every denomination and size.

Although Im committing to five years of classes, the stakes are anything but academic. As Rabbi Abraham Joshua Heschel wrote, We are either the last, the dying, Jews or else we are those who will give new life to our tradition.

Image by Courtesy

The author, slightly younger

This has been true of every generation. But now, the chief challenge preventing new life from emerging is caused not by antisemitism or assimilation, but by the very Jews who claim to be acting in our interests and as our leaders.

I do not believe the tropes that Millennial and Gen Z Jews are not joiners, that they only care about universalist ideas, that Jewish concerns are of minor or no importance to them. Young Jews not only want to build Jewish communities, they are building Jewish communities.

Many of these communities are on social media, but thats reality for generations that never had life without the internet.

And such community-building is also taking place IRL. The growth of independent minyanim is the most obvious religious example, but what surprises everyone I talk to is that Jewish life is thriving on college campuses nationwide both through traditional avenues like Hillel and Greek houses, and in hundreds if not thousands of student-created endeavors. Take it from a creator of the countrys only independent Jewish college guide: The notion that theres a crisis of antisemitism on campus preventing Jews from feeling safe, let alone thriving, is a lie peddled by unscrupulous groups hustling for donations by telling scared bubbes and zaydes that only those organizations can protect their grandkids.

Why does this narrative persist? Because the American Jewish donor class is more focused on Israel than on American Jewry.

The most important article the Forward published this decade was by a colleague who found that the largest share of donations to American Jewish causes 38% of a $26 billion pie went to pro-Israel advocacy. Only 16%, less than half that, went to Jewish education.

There is no Jewish future without Jewish education, but donors have decided to instead spend our inheritance (you could call it a birthright) on defending Israel from the Boycott, Divestment and Sanctions movement a campaign that even the Israeli government admits poses no threat to its economy rather than prioritizing the development of strong Jewish identities in the coming generations.

It brings to mind the story of Yiftach, the biblical judge who vowed that if God helped him save Israel from the Ammonites, he would sacrifice the first thing he saw when he returned home. Israel was indeed saved, but the sacrifice turned out to be his only child, who had run out to greet him.

Midrash Tanchuma says that Yiftach could have undone his vow if he had just gone to the High Priest for help but Yiftach thought the priest was an ignoramus, and the priest thought Yiftach was an idiot, so the worlds two most powerful Jewish leaders refused to cooperate with each other and the next generation was burned to ashes.

Studies have repeatedly shown that sending children to Jewish day schools and summer camps are the most effective ways of inculcating Jewish practices and identity, even when controlling for their parents involvement in Jewish life. Non-Orthodox day school graduates are twice as likely as public-school students to join a synagogue; summer camp kids are 21% more likely to feel that being Jewish is very important to them.

But these institutions are financially out of reach often unworthy of even consideration for all but the wealthiest Jews.

No way of life or world-outlook can long survive the stigma of being a class affair, Rabbi Mordecai Kaplan warned in 1934. Clearly, we havent listened.

If Jewish leaders want the coming generations to grow and thrive, they should underwrite Jewish day schools and summer camps to make them tuition-free. And since many parents will still prefer their children get a public-school experience, those leaders should also underwrite synagogues to make their Sunday schools tuition-free.

Ironically, the only prominent figures who appear to understand the importance of widely-available American Jewish education are Russian-Israeli leaders Avigdor Liberman and Natan Sharansky, who have repeatedly proposed that the Israeli government provide hundreds of millions of dollars in grants for U.S. day schools. You could read this cynically and see politicians concerned that the decline of American Judaism would mean a decline in American political and financial support for Israel. But it can just as easily be seen as Jews who fled countries with no Jewish future, alarmed by the prospect of American Jews choosing not to invest in their own future.

And even if some American Jewish megadonors truly only cared about defending Israel, the most effective way to do so would still be investing in Jewish education, rather than subsidizing campus BDS battles that are largely symbolic since, despite the outcomes of student votes, no university has yet actually divested.

Jewish students from Brown University

One of the countrys most prominent Jewish philanthropists recently tweeted, About 70% of Jews do not identify as Jewstheir new religion is Leftism. With that kind of attitude, its logical to single-mindedly support Israel as the eventual sole remnant of Judaism.

But that would mean missing not just the awe-inspiring determination of American Jews of all ages and incomes to maintain the established institutions they love despite unprecedented difficulties, but also the amazing new communities being built: on Jewbook and Jwitter, in independent minyanim and Jewish student networks, in non-traditional Daf Yomi study groups, through all sorts of experimental Zoom experiences, and most especially, in the incredible waves of social-justice activism that are proudly and consciously Jewish.

That includes perhaps especially includes IfNotNow.

Ive reported on this group and associated movements since they launched in 2014, and Im around the same age (and share the same day-school background) of many of their founders and leaders. Now that Im leaving journalism, I can openly say that I strongly disagree with most of IfNotNows statements and tactics.

But I also believe that IfNotNow, and the young Jews who have found a home in and around it, is a tremendous net positive for American Jewry. Because unlike past generations of Jewish leftists radicalized by Israeli depredations, this group refuses to check their Judaism at the door. They demand to be seen as proud Jews acting in the spirit of Jewish tradition and they are.

While some IfNotNow members are able to feel comfortable in established Jewish institutions that officially either despise or ignore them, many more feel alienated. Most are yearning to be accepted as they are by the broader Jewish community to be granted just enough tolerance to allow a sense of belonging from a family that they long to be part of even as they recoil from many of its mores (in other words, a family).

Jewish institutions that are interested in growing should do everything they can to make this generation of leftists feel welcome. This is not as difficult as it may seem. Chabad did not become the most successful Jewish movement of the last 50 years by telling Jews they disagree with to shove it. Instead, they say very clearly, This is what we believe, and we wont compromise on our values, but you are our family and are always welcome here.

Image by Photo: Gili Getz

IfNotNow Protests

I dont know if it will be possible to fully synthesize IfNotNow followers into broader institutions, to build not a big tent but a web that connects us all toward a common purpose even as we occupy different strands. And the tension goes both ways theres always been a bit of a disconnect on the Jewish left between those who merely want the establishment to respect their views and those who demand that the establishment adopt their views.

But if our institutions become more accessible not just financially, but also by being less machmir about who is and isnt kosher they will be opening the doors to thousands of young, creative, vibrant people who feel Jewish in their kishkes and want to build a brighter Jewish future for themselves and their future Jewish children.

Lots of people know the story of Honi the Circle-Maker, the Talmudic figure who once asked an old man why he was planting a tree he would never live to see blossom. Just as my ancestors planted for me, I too am planting for my descendants, the planter says. Honi then falls asleep for 70 years, and when he wakes up, he sees that the planters grandson is enjoying the fruits of that tree. Its a cute fable with an important message.

But most people dont know the rest of the story.

Honi then starts looking for his own grandson. He tells townspeople that he is Honi, but no one believes him. He goes to his beloved study hall, where he hears students praise him as a legendary scholar. But when he tries to explain that he is the famous Honi, hes jeered out of the building. Honi is so despondent that he dies.

This tale, a rabbi named Rava explains, is actually meant to explain the origin of a saying: Either friendship, or death.

The word for friendship in the saying, chevruta, is also the word for a study partner. So the phrase could just as easily be, Either education, or death.

Or, to read the story into the phrase in yet another way: Either community, or death.

Education and community-building: As a rabbi, this will be the work of my life. It will not be up to me alone to complete the tasks but neither am I free to abstain from them.

Aiden Pink is the deputy news editor of the Forward. Contact him at pink@forward.com or follow him on Twitter @aidenpink

Read the original:

Why Im leaving The Forward to become a rabbi - Forward

Kenosha residents say they’re wary of becoming backdrop for the 2020 presidential campaign – Milwaukee Journal Sentinel

Former Vice President Joe Biden, left, and President Donald Trump(Photo: Wire services)

KENOSHA Kenosha has become the political center of the country this week with a visit from President Donald Trump on Tuesday and a scheduled visit from Democratic presidential nominee Joe Biden onThursday.

But people in Kenoshaarent blind to the ambitions of the presidential hopefuls. Many interviewed Wednesday said they feel the two candidates, coming to Kenosha against a backdrop of civil unrest sparked by the police shooting of Jacob Blake,are hustling for votes in November.

Michael Charleston, a Kenosha resident for more than 20 years,said he felt that Trumps visit was toobrief,and he is wondering about Bidens real motivation behind the visit.

At the end of the day, what are you still doing for the city as a whole? Charleston asked. Are you trying to get votes to see if you can get re-elected? Or are you seriously trying to help?

In 2016 Trump carriedKenosha County over Democratic rival Hillary Clinton by less than 1%.

The laws need to change, Charleston said, regarding police accountability and transparency. (Trump) didnt really speaktoomuch to any of that. Letsfix these laws.

With these two visits, Charleston said, he would like to hear more specifics on what the candidates plan to change.

If things dont change and they stay the same, its going to be the same outcome, Charleston said.

The shooting of Blake, a Black man,by a white Kenosha police officer on Aug.23 caused days of massive protests and damage to local businesses.

During one protest, two people were killed and another was shot in the arm, allegedly by 17-year-old Kyle Rittenhouse, who has been charged with first-degree intentional homicide and five other felonies.Rittenhouse is seen in a video with armed men who said they were protecting a car lot in Kenosha.

Protesters have been calling for the arrest of Rusten Sheskey, the Kenosha officer who shot Blake, and for police departments to be held more accountable.

Trump toured the Uptown neighborhood of Kenosha, where much of the damage took place.

Biden and his wife, Jill, planto meet with the Blake family. Other plans for the trip haven't been announced. Biden told reporters Wednesday after a speech in Delaware that Sheskey should be criminally charged.

Tabitha Miller said neither candidate should come to Kenosha because the community is trying to heal.

There was a lot of concern from the citizens that Trump coming to town would bring all of this (tension) back up, Miller said, adding she feels the same about Bidens visit.

I understand the position of the president and he should come here and show the people he supports us. But as far as the timing of it, it really wasnt safe even for the citizens, let alone the president to come here or potential president.

Grant Howe isaschool social worker at Harborside Academy and Reuther Central High School, which is right across the street from Civic Center Park, the location of many protests.

It causes a lot more division, Howe said of the visits by the candidates. I think were healing right now.

Howe saidboth the Trump and Biden visits bringextra scrutiny to thearea, but he is interested in what Biden has to say.

If he does win the election, hes got to take some real steps to look at what Black Lives Matter are demanding and work on those things, Howesaid. The only way to stop whats going on is to work toward the justice that people are asking for.

FriendsSamebeToddandHedda Gandy came to Kenosha from Racine to look at the murals that have beenpaintedon the plywood that covers many windows and doors of Kenosha businesses.Neither is a Trump supporter.

What Trump has started has divided the country, Todd said. All of this was bound to happen soon. Who wouldve thought Wisconsin? I wouldve never thought it was going to be Wisconsin.

Todd said she wants to hear more from Biden on how communities like Kenosha can come together.

How is he going to start uniting people, Todd said. And nobody is ready to do that.

Gandy said its going to take a lot of work to heal some of the division that is in the country.

Its going to take more than just him to do that, Gandysaid about Biden unifying the country. Its bigger than Black and white.

Our subscribers make this reporting possible. Please consider supporting local journalism by subscribing to the Journal Sentinel at jsonline.com/deal.

Read or Share this story: https://www.jsonline.com/story/news/politics/elections/2020/09/02/kenosha-residents-say-they-wary-visits-trump-biden/5696568002/

Go here to see the original:

Kenosha residents say they're wary of becoming backdrop for the 2020 presidential campaign - Milwaukee Journal Sentinel

The State of Diversity and Inclusion Technology in the Workplace – CMSWire

PHOTO:Shutterstock

The technology landscape for diversity and inclusion programs is relatively new. A majority of the vendors (60%) are less than four years old, and most vendors have been around less than nine years, according to 2019 research from RedThread Research and Mercer.

Now is agood time for chief diversity officers and other leaders in D&I workplace programs to take a peek under the hood at these technologies. The D&I imperative is top of mind today with growing civil unrest, calls for social justice from organizations like Black Lives Matter, and recognition of the bias inherent in workplace systems of hiring, compensation and promotion and career development.

Ultimately the goal is to have technology to help mitigate our bias as humans and to have technology be able to in a proactive way help surface these opportunities for us to recognize some kind of bias and interrupt it, said Katy Tynan, principal analyst at Forrester who focuses on organizational and leadership development.

That's one of the ways that I see technology working across that entire landscape to be a bias interrupter. Its for us to say, I didn't realize I was thinking about it that way. And to be able to do that at scale, as opposed to on an individual basis.

Therein lies one of the strongest arguments for D&I technology: scaling diversity and inclusion across the organization, according to John Kostoulas, a senior director analyst atGartnerfocused on human capital management technologies. Companies that cant scale their D&I programs likely cant produce business results and wont instill a sense of confidence across the employee base that D&I is being taken seriously inside the organization, he said. Take the example of training to recognize the signs of unconscious bias.

You can do training for 200 people and that would be an easy thing to do, Kostoulas said. It will take you a couple of weeks then you break them into different classes and you do the training. Happy days and you're done. But how about doing this for 10,000 people? It's not something that can be scaled.

Technology can help scale these programs and get learning and development to the front line. That's a good thing, Kostoulas said, because D&I efforts are not only worthy in a moral sense but also a business one.

The front line is more and more where the pulse of the organization is and for the customers, its the face of the organization, Kostoulas said. Because of the speed that business is going into, these front line employees make more and more decisions, and therefore you need different perspectives, which is diversity, but you also you need to be able to have these perspectives coming together to produce a decision and this is inclusion. And this is where technology is coming in as a critical enabler of getting D&I right toward business performance and business results.

Related Article:Getting to the Heart of the Chief Diversity Officer's Agenda

D&I technologies are offered either as standalone features or as part of a suite within human resources technology or human capital management suites, according to analysts.

RedThread Research and Mercer noted that D&I technology is enterprise software that provides insights or alters processes or practices, at the individual or organizational level, in support of organizations efforts to become more diverse and inclusive. Their research did not include technologies that improve technology accessibility for the differently abled.

What return do users of this technology want out of these investments? Scalability and making sure their technology tools are widely available throughout many geographic locations, according to RedThread and Mercer researchers.

"In our conversations with customers," researchers reported, "they often indicated that they tend to prioritize technologies that seamlessly link to and integrate with their existing HR platforms rather than adding yet another tool to the mix."

RedThread and Mercer split D&I technology vendors into three areas:

According to D&I vendors in the RedThread Research/Mercer report, the problems these technologies are trying to solve include:

The outcomes of implementing D&I technologies comes with risks, according to the report. For example, technology may itself create or amplify bias, increase legal risks for failure to act on identified problems, enable employee perceptions of "Big Brother"-style monitoring and over-focus on political correctness.

The risk of implementing a biased technology is precisely why chief diversity officers or anyone buying D&I technology needs to work closely with technology experts like IT, according to Tynan. Technology itself can reflect the biases of the people who build it.

It requires a fairly nuanced understanding of what the tech can and can't do and in what ways the tech itself is biased," Tynan said. "Its well known that a lot of AI technology is biased.

HR may understand what they're driving at from a D&I perspective but they don't necessarily understand how the technology works, whereas the IT group understands the technology and what AI can do. And they're familiar with the terminology and are able to have a more nuanced conversation with a vendor. But at the same time they may not understand the D&I issues.

And so I think there needs to be this real partnership between HR and IT in order to take advantage of and avoid some of the challenges with this type of technology, Tynan said.

Related Article: How Companies Can Bake Diversity and Inclusion Into Their DNA

Gartner, in its January 2020 reportHow HCM Technologies Can Scale Inclusion in the Workplace, reported multiple ways technology supports D&I efforts. Mostly, the technologies are baked into a larger suite of offerings not marketed for D&I as a primary use but that have use cases for inclusion:

Kostoulos said oftentimes technology that supports D&I programs is not flagged as such but still can support inclusive outcomes. For instance, you can use Voice of the Employee technology to understand the sentiment around engagement as well as inclusion.

Until very recently, many of the vendors who were delivering solutions in all these areas would not actively position the technologies around the D&I objective, Kostoulos said. Those who were looking for a technology to tackle inclusion, they might have had the technology already in their solution and they didn't need to go and buy anything else."

Ultimately, Kostoulos said D&I isnt quite its own software category but rather an outcome for a number of software solutions to support. Gartner reports a fair share of vendors who produce these kinds of offerings such as Humanyze, Peakon and Humu.

RedThread and Mercers research reports 105 vendors that currently offer technology targeted at improving diversity and inclusion in organizations, including niche D&I vendors that focus on diversity and inclusion outcomes such as Advancing Women, InHerSight and Jopwell. They estimated the market worth at $100 million.

For a good amount of time, both vendors and buyers were focused on talent acquisition, Kostoulos said. And it was a number of smaller solutions that had to do with how we use AI to create the job description that is compelling and has diverse candidates. Or how do we use AI to match people with jobs so we mitigate selection bias. How do we run AI-driven assessments? How do we create structured interview guides? How do we run analytics on the different sources we get candidates from? So these were very popular and they're still very popular. In the last year, theres been more increased focus on pay equity and diversity analytics.

Related Article: 4 Ways to Embrace the Challenges of Diversity in the Workplace

Of special note, Forresters Tynan mentioned the D&I technology category related to community building and inclusive practices. She cited a listening program through an engagement pulse survey that helps organizations understand how people feel: whether they feel a sense of belonging, discriminated against and if they feel they have the same opportunities as others.

Were still talking about technology embedded within another technology, specifically a pulse survey or an engagement survey in a sentiment tool, but that's another way that companies are using technology to better understand their situation, Tynan said.

Collaboration tools like Workplace from Facebook, Salesforce Chatter, Microsoft Teams and Yammer can be used for community building and for intentional creation of inclusive communities within organizations.

Too often, organizations think of diversity and inclusion in terms of what Tynan called the Big Three gender, race and sexuality. But they often fail to look at other aspects like ability. Research indicates many people with disabilities have a problem with applicant tracking systems and struggle to complete job applications because the tools were not designed in an accessible manner.

"And so you end up with people who are marginalized in the talent acquisition process because of an issue with ability," she said. "They're unable to access the same information. And the same is true with customers. Is your actual product designed in an accessible way in order to be inclusive for people who may have disabilities? Those are the kinds of things to think about across the entire technology ecosystem.

Continue reading here:

The State of Diversity and Inclusion Technology in the Workplace - CMSWire

Members of Georgia football team gather outside Holmes-Hunter Building in support of social justice – Red and Black

Members of the Georgia football team gathered outside of the Holmes-Hunter Academic Building on Tuesday evening in support of social justice, according to a statement from Georgia athletics spokesperson Claude Felton.

Hunter Holmes Jr., son of Hamilton Holmes, one of the first Black students admitted to UGA and the namesake of the building alongside Charlayne Hunter-Gault, spoke to the team. Georgia head coach Kirby Smart also talked to his players at the organized event.

The event came just five days after a three and a half hour discussion arose out of a team meeting, where players and coaches brainstormed ideas on how they could cause change in the community.

Smart said in an Aug. 29 press conference via Zoom that the program talked about many of these issues over the summer, but players wished to revisit their concerns after police shot Jacob Blake in Kenosha, Wisconsin, on Aug. 23.

They have been very intentional about wanting action, Smart said in the virtual press conference. They want the University of Georgia, in terms of the athletic department, to represent them, they want to do things in the community, they want to give back to their communities. They want to make change.

Aside from Tuesdays gathering, Georgia football players, such as senior linebacker Monty Rice, have been active on social media voicing support for the Black Lives Matter movement. Other players, such as senior linebacker Jermaine Johnson, have also spoken to the media on their desire for change.

Everything has struck me and my teammates, whether theyre white or Black, because were united here. Were brothers, Johnson said in a virtual press conference on Aug. 31. Those types of issues affect all of us.

View post:

Members of Georgia football team gather outside Holmes-Hunter Building in support of social justice - Red and Black

How to defund the police without creating another George Zimmerman – Insider – INSIDER

Police in Kenosha, Wisconsin, said that a 911 call involving a "domestic incident" took them to Jacob Blake's neighborhood on August 23.

The 29-year-old Black man was shot seven times in the back within three minutes of officers arriving, according to dispatch audio pieced together by the Milwaukee Journal Sentinel.

The accounts leading up to that encounter vary.

Blake's defense team says he was trying to break up a fight, according to NPR. A police report says that "a female caller reported that her boyfriend was present and was not supposed to be on the premises." It also describes officers trying unsuccessfully to take Blake into custody.

The Blake shooting has reinvigorated Black Lives Matter protests around the United States, which swelled after the killing of George Floyd in May. The movement has included a call to "defund the police" generally understood to mean diverting funding from police departments to other community resources.

Asked how else the Blake situation could've been handled, Sean Blackmon, a spokesperson for the Stop Police Terror Project DC, a police reform advocacy organization, replied: "I would suggest not shooting him in the back seven times."

Blackmon wasn't trying to be flippant. He said police, too often, resort to violence when things don't go the way they want.

"We have to ask ourselves: Was Jacob Blake shot ... and partially paralyzed because he wouldn't leave the premises? Or because he refused to obey the word of a cop? And to police, not doing every single thing they say is a crime worthy of death," he said.

Paige Fernandez, policing policy advisor for the ACLU National Political Advocacy Department, took it a step further, saying that armed police officers should never have been at the scene to begin with.

"Even if they did respond," she said, "they shouldn't have been armed, and there shouldn't have been multiple police. Police didn't de-escalate that situation they escalated it and tried to murder a man. They are unreformable, and we must work to shrink their role and responsibilities, so they aren't able to cause further harm."

Activists and policy experts who spoke to Insider believe that public safety should be in the hands of the community.

But that's not without its issues: George Zimmerman, a neighborhood watch captain in Sanford, Florida, shot and killed 17-year-old Trayvon Martin in 2012 after reporting that the teenager appeared "suspicious."

A young boy holds a sign during a protest against the death in Minneapolis police custody of African-American man George Floyd, in St Louis, Missouri, U.S., June 1, 2020. Picture taken June 1,2020 Lawrence Bryant/Reuters

He had pursued Martin even though a 911 dispatcher told him not to, taking matters into his own hands. Zimmerman was ultimately acquitted of murder in the case, claiming he shot Martin in self-defense.

Eight years later, Travis and Gregory McMichael hopped into their truck and chased Ahmaud Arbery through their Georgia neighborhood based on the belief that he resembled a burglary suspect. The 26-year-old Black man was gunned down during that encounter. After the case was passed between several district attorneys, the McMichaels were charged with murder weeks after the incident.

Blackmon described those crimes against Black people as acts of "racist vigilantism," and stressed the need for "organized democratic community-based public safety."

A warrant had been issued for Jacob Blake's arrest in July. He was charged with felony sexual assault and disorderly conduct and criminal trespassing, both misdemeanors, according to Wisconsin court records. The Wall Street Journal reported that the charges stemmed from his girlfriend who is also the mother of three of his six children telling police that Blake entered her house, digitally penetrated her without her consent, and took off with her car and debit card.

On Friday, Kenosha Police Chief Daniel Miskinis said he couldn't confirm whether the aggressive approach taken by police was connected to the warrant for sexual assault in the domestic abuse case.

But Melina Abdullah, a co-founder of Black Lives Matter who told Insider she's personally experienced domestic violence said the issue wasn't relevant. Blake's fate isn't justice, she said.

"I don't know a survivor who wants the outcome that was meted out on Jacob Blake for even their abuser," she said. "What they want is an end to the abuse."

Melina Abdullah, of Black Lives Matter, addresses the crowd during a demonstration to ask for the removal of District Attorney Jackie Lacey in front of the Hall of Justice, in Los Angeles, California, on June 17, 2020. VALERIE MACON/AFP via Getty Images

Abdullah turned to her brother for support. But not everyone can depend on their family like she did, she said. That makes it critical for American society to be "creative and thoughtful and restorative and transformative in our approach to justice."

"We really believe that the answer to all of this is investing in community," she added. "So even if you don't have a wonderful blood brother like I do, you can have the community ... offer what you need."

Abdullah views a budget as "a statement of values and priorities," adding that cities would be better off if put taxpayer dollars were used community resources on the "front end," helping people in need, rather than pouring billions of dollars into police agencies every year. Her plans would involve abolishing police departments as we currently know them.

"The police are basically there to respond to crime," but "interventionists and prevention workers can actually bring peace to neighborhoods," Abdullah said.

For his part, Blackmon took a long view of policing in the United States. He said the current policing system is worse-off for disadvantaged people, including people of color. The result of this centuries-old status quo is a build-up of "resentment and frustration," he said, and "the police are put in place to keep a lid on the pot of frustrations."

Reducing the size of a police department is not enough, he said, calling for a holistic approach that is fueled by the "intentional reinvestment" of funds into better education, affordable healthcare, employment opportunities, youth services, and community-led peacekeeping efforts.

Fernandez echoed the sentiment, noting that the ACLU supports divestment and specifically uses that term because it's "not a police or prison abolitionist organization."

Instead, she said, the ACLU believes "we need more investment in communities of color that have suffered from decades of underinvestment in everything except police, racist policies, and their related punitive programs. If we invested more in prevention, many domestic incidents wouldn't have happened in the first place."

Police in riot gear stand outside the Kenosha County Court House Monday, Aug. 24, 2020. AP Photo/Morry Gash

It's important for higher-ups to fund "community-based and community-led interventions," Fernandez added, because "communities know how best to respond to harm in them, and it's important we foster accountability on the local level."

Abdullah believes that the next Zimmerman or McMichael can be avoided by ensuring that those who are tasked with safeguarding a community come from within it and can understand its pain points.

So Black neighborhoods, for instance, would be empowered to look internally when it comes to their own safety.

"We want the community that's most impacted by violence to be the providers of security," she said. "We want community members to be able to determine what security looks like for them."

This article has been updated.

The rest is here:

How to defund the police without creating another George Zimmerman - Insider - INSIDER

Deesha Philyaws new story collection is window into the rich, varied lives of Black women – PGH City Paper

click to enlarge

CP Photo: Jared Wickerham

Deesha Philyaw

I think about what Toni Morrison said about Ralph Ellison titling his book Invisible Man, Philyaw says. She said, Invisible to whom? Were not invisible to ourselves, but as a larger society, when we look at what we call our canon, when you think about the books that kids have to read in high school or college, its not always reflective of the whole of who we are as a culture.

Philyaw will launch her book tour for The Secret Lives of Church Ladies with a virtual appearance on Thu., Sept. 3 as part of the Pittsburgh Arts & Lectures Made Local series.

The stories in Secret Lives are richly rendered tableaus of the lives of Black women. In Peach Cobbler, a young girl misinterprets her mothers liaison with a pastor, thinking shes dating God. Instructions for Married Christian Husbands is a not-so tongue-in-cheek manual for men seeking to have an affair. And Jael, arguably the books centerpiece, features the alternating voices of a teenager and her great-grandmother, illustrating the gulf between them.

CP Photo: Jared Wickerham

Deesha Philyaw

I think about myself as a child, as a girl, watching church ladies, Philyaw says, but also watching women outside of church. And even within the church theres a diversity of types. And as a kid, youre watching and thinking, Who am I going to be? And so often, were presented either with a monolith, or were presented with a binary: youre going to be the whore or the Madonna, in the church or out of the church, when real life is just not that black and white. It was important to me that the women and girls in the stories were different ages. They had different mindsets and experiences and outlooks.

The Secret Lives of Church Ladies is being released during a time of burgeoning awareness of Black communities and culture in the U.S. Philyaw acknowledges that theres been a corresponding increase in interest in these types of stories which have been traditionally overlooked.

We have to be really intentional about seeking stories about experiences that arent our own, Philyaw says, and that havent been spoon fed to us from day one that these are the stories worth reading. We have to reject that, all of us, and read more broadly. I think were at a moment now where folks are reaching out to that. Were in this moment where were seeing the interconnectedness of our stories, were seeing stories that have been left out. And this pandemic certainly shows us how were connected and rely on each other to survive, literally to survive. And we havent been good at that as a country. Thats not our history.

Made Local: Deesha Philyaw

A video conversation with Khirsten Scott, assistant professor of English at the University of Pittsburgh, presented by Pittsburgh Arts & Lectures. 6 p.m. Thu., Sept. 3. Free, but registration is required. pittsburghlectures.org

See the original post:

Deesha Philyaws new story collection is window into the rich, varied lives of Black women - PGH City Paper

Latinx Meaning: The Origin and Importance of the Inclusive Term – GoodHousekeeping.com

Latinx, a gender neutral alternative to Latina and Latino, is a term that has recently gained a presence in popular culture. The term is used to describe the diverse group of people who have roots in Latin America. Because the Spanish language classifies most words as masculine or feminine, the term Latinx emerged out of an act of solidarity to include LGBTQIA+ folks who may not want to be classified as male or female. Latinx is an intersectional term that aims to include all people of Latin American descent.

Latinx is an inclusive term that can collectively refer to people who identify within and outside the gender binary, say Alan Aja, a professor in the Puerto Rican and Latin Studies department at Brooklyn College, City University of New York, and Maria Scharrn-del Ro, a professor in the School Counseling Program at the same institution.

The term Latinx emerged from the Spanish-speaking queer community to challenge the gender binary, explain Aja and Scharrn-del Ro. While the exact origin of the term is unclear, its use can be traced back to online queer community forums. Some researchers have found early uses of the x in place of the gendered o and a dating back to the late 1990s. The term became recently popularized, however, after the devastating Pulse massacre in 2016, the mass shooting that occurred at a gay nightclub in Orlando, Florida.

We found that after the Pulse Massacre, Latinx was thrust into larger use, say Aja and Scharrn-del Ro. Perhaps as an act of resistance, solidarity, and visibility of non-binary gender identities as the LGBTQ+ [community] was being attacked.

Because Spanish is a language with grammatical gender, certain words are used to describe men and others are used to describe women. Latino and Latina are gendered variants of Latinx, explains Eve Rosenfeld, a Ph.D. candidate in Psychology at the University at Buffalo who researches identity invalidation in Black and white Latinxs. Latino encompasses male-only groups of Latinx individuals, as well as mixed-gender groups of Latinx individuals. Latina encompasses female-only groups of Latinx individuals.

Some say the use of Latina and Latino, however, can be exclusionary and inequitable. Using these gendered terms ignores those with genders that fall outside of the male-female binary. Additionally, the gendered terms center men over women, says Rosenfeld.

Yael Rosenstock Gonzalez, an author and identity coach, breaks it down for non-Spanish speakers. An English equivalent of Latino is the use of mankind to refer to all humans, she says. While mankind is understood to include women and potentially other genders, the name is inherently masculine.

The term Hispanic, on the other hand, refers to an ethnic group in the United States that has its cultural origins in Spanish-speaking countries. Youll find the term on any federal or state form, college application, or employment paperwork. The label, however, has been flagged as problematic by members of the Latinx community. Using Hispanic assumes that every Latinx individual speaks Spanish, when they may only speak their indigenous languages; it also excludes Brazilians because they speak Portuguese. In addition, Hispanic was first used on U.S. census forms in 1980 and has been tied to a whitening ideology. According to writer Araceli Cruz in her article The Problematic History of the Word Hispanic, it is a term that has racist undertones and has been described as whitewashing the unique heritage of Latinx people.

Latinx is most commonly pronounced Latin-EX. It is also sometimes pronounced la-TEE-nex or La-TEENKS.

Here are the different ways you can use the term in a sentence, explains Rosenfeld:

While Latinx is a word created with inclusivity in mind, not everyone supports its use. Some people think that Latinx is an elitist term that is mostly used in academic settings. It has also been called out as a form of linguistic imperialism, meaning some think the term Latinx represents English policing the Spanish language in a way that doesnt correspond with its grammar or conventional way of speaking. Because Latinx doesnt sound like other words in Spanish, it could also potentially alienate non-English speaking people of Latin American descent.

Rosenstock Gonzalez offers an alternative: the term Latine (pronounced La-TEEN or Latin-EH). She says, The use of e does not have gendered associations. For example Latine, elles, todes, amigues all of which would be easier to incorporate into the Spanish sounds that already exist and is therefore an easier sell to Spanish speakers.

While a single word may never perfectly describe such a diverse and rich culture, using intentional language counts. The use of Latinx and Latine is an act of solidarity and resistance against the violence that racist, sexist, heterosexist, classist, xenophobic, ableist, and other oppressive structures inflict in our communities, say Aja and Scharrn-del Ro.

Natalia Sylvester, author of the YA novel Running about a Latinx teen whose father is running for president, says, The term Latinx may not be a perfect one, but the willingness to change (and more importantly, to listen to the LGBTQ community on this) is vital.

Given the escalating violence enacted against Latinx people, allies must step up to the plate. To start, employ the language they ask you to use. Then, listen, align, and act.

To be an ally to Latinx people is to first and foremost acknowledge the terms legitimacy and respect someones choice to use it, even if you choose not to, says Nicholas Patino, a photographer and community leader based in Miami.

Rosenfeld offers an imperative: The most important thing to do as an ally is to listen, non-defensively, she says. Support our causes. Fight against ICE. Dismantle your own racism. Don't invalidate our identities, even if our appearance diverges from your expectations. Don't assume things about us based on our identity. Not all of us are immigrants. Not all of us speak Spanish. We are extremely diverse. Recognize that diversity. Center your allyship around our voices.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

View original post here:

Latinx Meaning: The Origin and Importance of the Inclusive Term - GoodHousekeeping.com

Dylann Roof and Kyle Rittenhouse Are Proof That Racism Won’t Just "Age Out" – HarpersBAZAAR.com

MediaNews Group/Reading Eagle via Getty Images

The shooting of Jacob Blake on August 23 brought the city of Kenosha, Wisconsin and those of us watching across the country to its knees. This is a natural reaction: to watch a man shot seven times in the back is traumatic for anyone. But imagine being one of his three sons, strapped in a car seat, hearing those seven rounds, and then seeing Daddy drop to the ground seemingly lifeless. Or imagine being one of the many community members who had just witnessed Blake break up a fight and were now watching officers stand over his body. Imagine being the family member who received that call. Its no wonder that this community, grateful for Blakes survival but outraged at the callous behavior of officers on the scene, would begin protesting immediately.

As is often the case in this country, protesters seeking accountability and cathartic release of their righteous anger were met with tear gas, mass arrests, and rubber-capped metal bullets. Three days later, protesters in Kenosha were also met by Kyle Rittenhouse, a teen who traveled from neighboring Illinois to become a frontline mercenary for white supremacy. The 17-year-old was shown on video brandishing an AR-15 and is charged with killing two protestors, Joseph JoJo Rosenbaum and Anthony Huber, and injuring a third man, Gaige Grosskreutz, who is expected to survive." Not only did Rittenhouse evade arrest despite protesters pointing him out to police as the shooter, he also wouldnt be apprehended until he was back across state lines and in his hometown of Antioch, IL the following morning. Days later, the president even defended him. The shooting and subsequent handling of the crime has led many in mainstream media to wonder what could bring a young man to such violence and why officers on site wouldnt bring him in. Unfortunately, those asking these questions have yet again underestimated white supremacy and its regenerative nature.

Rittenhouse, a self-identified aspiring cop, drove to Kenosha armed and ready to defend property in a community that wasnt even his own. According to interviews with former classmates by Vice News, His clothes were often branded with pro-police slogans, and he carried a Blue Lives Matter phone case. Rusten Sheskey, the officer who shot Blake in his back, is also on record having always wanted to be a member of law enforcement after watching his grandfather work as an officer for more than three decades. In order to understand these mens behaviors we need to understand what they have been socialized into believing is the job description of a cop and how society has empowered them to act on those beliefs. The history of policing in this country has been one of stifling dissent and using brute force to maintain a racialized status quo. That media have also glamorized police work as a necessity for our safety has only further cemented the urge that people like Rittenhouse and Sheskey feel to protect authority, especially at the expense of Black lives.

Color of Change, one of the nations leading racial justice organizations, recently released the report, Normalizing Injustice: The Dangerous Misrepresentations That Define Televisions Scripted Crime Genre, exploring the idea of cop-aganda which justifies police misconduct as collateral damage in delivering community safety. While the study talks generally about who shapes these narratives (disclaimer: predominantly white men) and how often people of color and, specifically, Black people are depicted as dangerous, we can and should take it a step further when thinking about how young white boys are being indoctrinated to become future Detective Stablers, abusing power.

In a country with literal monuments erected to enslavers and mass murderers, we have all but loaded the gun for Rittenhouse and other disgruntled white teens.

Everything about our country, from television/film to video games, has taught young people that officers must be listened to no matter what. The kind of person who aspires to that amount of authority and blind allegiance is then trained and coached into evading accountability and justifying their actions with racist tropes. And in a country with literal monuments erected to enslavers and mass murderers, we have all but loaded the gun for Rittenhouse and other disgruntled white teens. Rittenhouse is really the rule, not the exception, and everything his 17 years of life have taught him has led to this moment. Had it not happened now, would he have been the next George Zimmerman a decade later? Or would he have succeeded in becoming an officer and then been awarded with pension and paid administrative leave for killing people on the job? He did exactly what he was raised to do and therein lies our societal problem.

Racism will not fade out like the last song at a dance party. The shock and outrage we feel when we realize that, must be coupled with intentional action. So, what can we do? We need to cut off racisms life source and make a commitment to sustainable change, as Jacob Blakes sister Letetra Widman said. Considering every aspect of our society defaults to white as right, it will take a consistent effort to root out that little voice in all of us which registers white as superior whether we acknowledge it or not. This goes beyond our criminal justice system; it also includes medical racism which gives greater credibility to the opinions and pain of white people consistently over people of color. It includes the segregated social circles which, though seemingly harmless, ultimately hoard professional access and power in a culture where success depends on who you know. And of course, it includes the countrys broken education system, a result of our insistence on separate and unequal schooling, which is exacerbated under a pandemic where wealthy white students access private learning pods while communities of color are thrown to the wolves. These are all byproducts of white supremacy and must be addressed head on.

We need to have conversations with boys and men about combating entitlement before its too late.

We also have to recognize that this is a prime example of why reverse racism cant and doesnt exist. Racism is about power; not simply prejudice. Had Rittenhouse hated those protesting yet stayed home, that hate would be his problem. But when multiple people are shot, his heroes and future colleagues congratulate him, and when he is reassured and tucked into his bed that night it became our problem. Intentional anti-racist parenting needs to be normalized through diverse books or toys and honest conversations about the reality of race in this country. Acknowledging the ways that toxic masculinity consistently manifests into deadly violence is another part of disrupting this power. We need to have conversations with boys and men about combating entitlement before its too late.

Lastly, we must demand a concerted effort to keep digital platforms from becoming radicalization centers for white supremacists and hate groups. These beliefs do not exist in a vacuum, and they can be turned into actions in virtual spaces. Social media is no longer novel, and its impact is clear. We must begin the process of regulating the ways violence is organized right under our noses. From Dylann Roof, to Nikolas Cruz, to the white supremacists of Charlottesville, to Kyle Rittenhouse, racists always pass the baton. Societal refusal to take this seriously is a pandemic in and of itself.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Read the original post:

Dylann Roof and Kyle Rittenhouse Are Proof That Racism Won't Just "Age Out" - HarpersBAZAAR.com

Drexel professor’s app allows choir members to create music apart but together – Generocity

Drexel Universityprofessor and technologistDr. Youngmoo Kimsings in an a cappella group in his free time and was looking for a way members of his singing group could still create music together while practicing social distancing during the pandemic.

After looking around theApple App Store, he didnt find any solutions. That gave him the motivation to createVirtual Chorister.

As a musician, Kim found unique challenges that affected the way chorale members tried to create music when separated differences in internet speeds could cause delays when recording the same music, for instance. Also, Kim found that several of the singers trying to record their chorale parts were using two devices at once, and he realized that many people dont have the resources to do that.

In trying to make the experience of recording chorale parts easier, Kim was able to focus onhowpeople create music, first.

This is about singing, said Kim, founding director of the cross-departmentalExCITe Center, which intersects art and science. This is not about being a technologist. A lot things written by technologists are not for regular people. This was my way of making things easier. This is a great way to keep singing through the pandemic. Nothing beats being onstage for a chorale singer, but this is a way that we can continue to collaborate, express ourselves and do things musically.

Through Virtual Chorister, a conductor or choir director can provide a reference video with which choir members can synchronize, and after recording their part, choir members can upload their video to the app. Once every members section is uploaded, a user can combine every section to make a complete recording.

Kim has extensive experience in designing music software, thanks to a previous role withDigidesignwhere he designed plug-ins forProTools, a benchmark recording software that revolutionized the music industry. To code Virtual Chorister, he usedXCodeto write the app inSwiftusing standard iOS software development kitSDK.

For Kim, designing an app that could help vocal musicians sing remotely with each other was also a challenge to basic laws of physics. Kim explained that electrical signals are less resilient as the distance separating them increases and as a result, the best way to collaborate remotely is within 100 miles. While Virtual Chorister does not overcome the 30 millisecond delay limit, he wanted to create an app that could come as close to doing that as possible.

We have experimented with systems that let you do things in real time over the internet, he said. If you can get less than 30 milliseconds [of delay], it would almost work. Its about the delay you would get onstage from one end to the other. Its tolerable, but even if you have a good internet connection, keeping it under 30 milliseconds is hard.

Kimis a proponentfor helping communities affected by the digital divide find solutions. Making the app available for free was an intentional decision so that it could be accessible to school choirs and other groups that may lack funding.

School choirs and youth choirs are facing an enormous challenge this year, he said. This is a free app and hopefully helps more school conductors and music directors that want to get over speed bumps and challenges. Its very doable, it just takes a little bit of know how.

Virtual Chorister is currently only available on Apple iOS, but Kim is open to collaborating with Android developers to create a version for Android devices.

More:

Drexel professor's app allows choir members to create music apart but together - Generocity